Intellia Therapeutics Inc (NTLA)

Neuromuscular Disease · registered primary completion 2027-07-01 · NCT06672237

Published 2026-09-02Market cap $1,803M8 sourced statements

A Phase 3 Study of NTLA-2001 in ATTRv-PN · PHASE3 · n=60 · recruiting

Market

fact

No approved product carries Neuromuscular Disease on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT06672237: randomized, quadruple-masked, 60 participants (estimated). Primary outcome: Modified Neuropathy Impairment Score +7 (mNIS+7). 1 further primary outcome(s) registered.

Source: ClinicalTrials.gov record

Runway

fact

Cash of $438M against operating outflow of $109M per quarter gives roughly 4.0 quarters of runway, clearing the registered primary completion 3.4 quarters out by 0.6 quarters.

Source: 10-Q filed 2026-08-06

Share count and dilution

fact

140,126,693 shares outstanding against 152,265,693 if every outstanding option, warrant and convertible were exercised. In that case 8.0% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-06

fact

Share count up 30% year over year to 140,126,693 as of 2026-07-31.

Source: cover-page share counts (XBRL)

Regulatory

fact

Designations disclosed: RMAT, Breakthrough Therapy, Fast Track, Orphan Drug. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-06

Pipeline

fact

5 distinct molecules in 4 active company-sponsored trials; NTLA-2002 accounts for 2 of them at Phase 1/Phase 2/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 3.5%.

Source: DEF 14A filed 2026-04-30

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.